H. Lundbeck A/S (LON:0ABR)

Market Cap	4.08B
Revenue (ttm)	2.57B
Net Income (ttm)	368.84M
Shares Out	n/a
EPS (ttm)	0.37
PE Ratio	11.05
Forward PE	6.90
Dividend	0.11 (0.36%)
Ex-Dividend Date	Mar 27, 2025

Volume	4,120
Average Volume	3,100
Open	30.75
Previous Close	30.50
Day's Range	30.55 - 31.30
52-Week Range	23.30 - 41.70
Beta	n/a
RSI	52.88
Earnings Date	Aug 20, 2025

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati...

• Industry: Pharmaceutical Preparations
• Founded: 1915
• Employees: 5,707
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ABR

Financial Performance

In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.

Financial numbers in DKK